- No file added yet -
Supplementary Tables 1-5: Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis
dataset
posted on 2021-11-26, 12:03 authored by Lecai Xiong, Yi Cai, Xiao Zhou, Peng Dai, Yanhong Wei, Jinping Zhao, Hexiao TangSupplementary Table 1. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis
Bayesian ranking results of network meta-analysis. PlaCT= platinum-based chemotherapy. <1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%.
Supplementary Table 2. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis
Bayesian ranking results in patients previously untreated, in patients receiving checkpoint inhibitors monotherapy or combination therapy subgroups. The number in each cell represents the posterior probability of the row-defining treatment being ranked at the column defining position. PlaCT= platinum-based chemotherapy. <1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%.
Supplementary Table 3. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis
Bayesian ranking results in patients with advanced lung cancer receiving PD-1 inhibitors or PD-L1 inhibitors subgroup. The number in each cell represents the posterior probability of the row-defining treatment being ranked at the column defining position. <1%=patients with PD-L1 expression less than 1%; 1-49%=PD-L1 expression is greater than 1% and less than 50%; ≥50%=PD-L1 expression more than or equal to 50%. immunotherapy= immune checkpoint inhibitor; Prior+chem=previously treated with platinum-based chemotherapy.
Supplementary Table 4. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis
Bayesian ranking results for patients with PD-L1 TPS<1%, TPS 1-49% and TPS≥50% subgroups. Platinum=platinum-based chemotherapy.
Supplementary Table 5. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis
I2 values and Comparisons of the fit of consistency and inconsistency models using deviance information criteria (DIC).
